Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PTEN deficiency facilitates the therapeutic vulnerability to proteasome inhibitor bortezomib in gallbladder cancer.

Cancer letters - 31 Mar 2021

Jiang Tian-Yi, Feng Xiao-Fan, Fang Zheng, Cui Xiao-Wen, Lin Yun-Kai, Pan Yu-Fei, Yang Chun, Ding Zhi-Wen, Zhang Yong-Jie, Tan Ye-Xiong, Wang Hong-Yang, Dong Li-Wei

Abstract excerpt

Gallbladder cancer (GBC) is an aggressive malignancy of biliary tract with poor prognosis. Although several studies have shown the frequency of relevant genetic alterations, there are few genetic models or translational studies that really benefit for GBC treatment in the era of precision medicine. By targeted sequencing and immunohistochemistry staining, we identified that phosphate and tension homology deleted...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bortezomib
Share to Down-Regulation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gallbladder Neoplasms

Share to HEK293 Cells

Share to Proteasome Endopeptidase Complex

Share to PTEN Phosphohydrolase

Share to Survival Analysis

Share to Xenograft Model Antitumor Assays

Source

Identifiers

PMID: 33220333
DOI: 10.1016/j.canlet.2020.11.016

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PTEN deficiency facilitates the therapeutic vulnerability to proteasome inhibitor bortezomib in gallbladder cancer.PMID 33220333Read ↗

MAP kinase and mammalian target of rapamycin are main pathways of gallbladder carcinogenesis: results from bioinformatic analysis of next generation sequencing data from a hospital-based cohort (NCT05404347).Semantic proximity Read ↗

Genomic and molecular landscape of gallbladder cancer elucidating pathogenic mechanisms novel therapeutic targets and clinical implications.Semantic proximity Read ↗

MAP Kinase and mammalian target of rapamycin are main pathways of gallbladder carcinogenesis: Results from bioinformatic analysis of Next Generation Sequencing data from a hospital-based cohortSemantic proximity Read ↗

Integrative proteogenomic analysis provides molecular insights and clinical significance in gallbladder cancer.Semantic proximity Read ↗

Precision oncology for gallbladder cancer: insights from genetic alterations and clinical practiceSemantic proximity Read ↗

Comprehensive clinicopathological and genomic profiling of gallbladder cancer reveals actionable targets in half of patientsSemantic proximity Read ↗

Genomics of gallbladder cancer: the case for biomarker-driven clinical trial design.Semantic proximity Read ↗

Identification of MAP kinase pathways as therapeutic targets in gallbladder carcinoma using targeted parallel sequencing.Semantic proximity Read ↗

Transcriptomic landscape of Gallbladder cancer reveals altered pathways related to cell cycle and Aurora kinaseSemantic proximity Read ↗

Role of aberrant PI3K pathway activation in gallbladder tumorigenesisSemantic proximity Read ↗

Somatic genetic aberrations in gallbladder cancer: comparison between Chinese and US patientsSemantic proximity Read ↗

miR-539-5p inhibits proliferation and invasion of gallbladder cancer cells by targeting BACH1Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.